ScienceDaily: Top Health News |
Leveraging space to advance stem cell science and medicine Posted: 30 Dec 2021 10:09 AM PST |
Scientists retool CAR T cells to serve as ‘micropharmacies’ for cancer drugs Posted: 30 Dec 2021 10:09 AM PST Immunotherapies called chimeric antigen receptor (CAR) T cells use genetically engineered versions of a patient's own immune cells to fight cancer. These treatments have energized cancer care, especially for people with certain types of blood cancers. Now, scientists have developed new CAR T cells that can do something their predecessors cannot: Make drugs. |
Cancer deaths rose to 10 million worldwide in 2019 Posted: 30 Dec 2021 10:09 AM PST |
Best time for COVID-19 vaccination during your pregnancy may be now, study finds Posted: 29 Dec 2021 10:35 AM PST |
Healthy diet in early pregnancy reduces risk of gestational diabetes Posted: 29 Dec 2021 10:35 AM PST |
Substantial weight loss can reduce risk of severe COVID-19 complications, study finds Posted: 29 Dec 2021 10:35 AM PST |
Stopping dementia at the nose with combination of rifampicin and resveratrol Posted: 29 Dec 2021 05:42 AM PST Researchers have shown in mice models of Alzheimer's disease, frontotemporal dementia, and dementia with Lewy bodies, that the intranasal administration of rifampicin and resveratrol in combination is safer and improves cognitive function more than rifampicin alone. The research results are expected to lead to the development of safe and effective nasal spray for the prevention of dementia. |
Posted: 27 Dec 2021 12:43 PM PST |
Immune response to seasonal coronaviruses may offer protection against COVID-19 Posted: 27 Dec 2021 12:41 PM PST Researchers have found that individuals with a certain HLA type may be able to mount a killer T cell response to COVID-19, thanks to the T cells responding to a portion of the virus's spike protein that is also present in seasonal coronaviruses that cause the common cold. This work could help explain the different responses between populations, and could potentially be used as a way to develop a new type of vaccine against the disease. |
Parkinson’s protein blueprint could help fast-track new treatments Posted: 23 Dec 2021 07:14 AM PST Researchers have solved a decade-long mystery about a critical protein linked to Parkinson's disease that could help to fast-track treatments for the incurable disease. The research has produced a 'live action' view of the protein, called PINK1, in exquisite molecular detail. The discovery explains how the protein is activated in the cell, where it is responsible for initiating the removal and replacement of damaged mitochondria. When the protein is not working correctly, it can starve brain cells of energy, causing them to malfunction and -- in the long term -- die, as happens to dopamine-producing cells in Parkinson's disease. The discovery is the culmination of a project spanning eight years and provides the first detailed blueprint for the discovery and development of therapeutic agents that could help to slow or even stop the progression of Parkinson's disease. |
'Heavy' hydrogen stabilizes drugs Posted: 23 Dec 2021 07:14 AM PST Researchers have presented a method that allows the heavier hydrogen 'brother' deuterium to be introduced specifically into many different molecules. The deuterated compounds obtained in this way are more stable against degradation by certain enzymes. Drugs produced using this method can be effective for longer, meaning they have to be taken in lower doses or less frequently. |
DNAzymes – how active DNA molecules with therapeutic potential work Posted: 22 Dec 2021 12:31 PM PST |
Flexibility may be the key to potent peptides for treating diabetes Posted: 22 Dec 2021 12:30 PM PST |
Academic education can positively affect aging of the brain Posted: 22 Dec 2021 12:30 PM PST |
STANN reveals new insights into how the brain functions Posted: 22 Dec 2021 12:30 PM PST |
How brain cells die in prion diseases Posted: 22 Dec 2021 12:30 PM PST Prion diseases, such as Creutzfeldt-Jakob Disease (CJD), are fast-moving, fatal dementia syndromes associated with the formation of aggregates of the prion protein, PrP. How these aggregates form within and kill brain cells has never been fully understood, but a new study suggests that the aggregates kill neurons by damaging their axons, the narrow nerve fibers through which they send signals to other neurons. |
You are subscribed to email updates from Top Health News -- ScienceDaily. To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States |